EGFR and nasopharyngeal carcinoma: In the present study, 94.9% of NPC patients expressed EGFR, including 77.7% whose EGFR expression exceeded 25%, corroborating Chua’s study [24] The efficacy of induction therapy combined with anti-EGFR was related to EGFR (P = 0.015).